Compare HIW & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIW | CPRX |
|---|---|---|
| Founded | 1978 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.9B |
| IPO Year | 1995 | 2006 |
| Metric | HIW | CPRX |
|---|---|---|
| Price | $33.13 | $31.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $27.57 | ★ $35.00 |
| AVG Volume (30 Days) | 2.0M | ★ 2.0M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 8.43% | N/A |
| EPS Growth | ★ 54.26 | 28.24 |
| EPS | 0.29 | ★ 0.50 |
| Revenue | ★ $806,112,000.00 | $119,072,803.00 |
| Revenue This Year | $6.03 | $9.20 |
| Revenue Next Year | $3.58 | $10.51 |
| P/E Ratio | $115.07 | ★ $62.98 |
| Revenue Growth | N/A | ★ 16.39 |
| 52 Week Low | $20.45 | $19.05 |
| 52 Week High | $33.47 | $32.56 |
| Indicator | HIW | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 73.66 | 70.31 |
| Support Level | $25.13 | $31.25 |
| Resistance Level | N/A | $32.56 |
| Average True Range (ATR) | 0.76 | 0.04 |
| MACD | 0.08 | -0.05 |
| Stochastic Oscillator | 85.19 | 86.96 |
Highwoods Properties Inc is a fully integrated office REIT that owns, develops, acquires, leases, and manages office properties mainly in the best business districts of Atlanta, Charlotte, Dallas, Nashville, Orlando, Raleigh, Richmond, and Tampa. Its principal business is the operation, acquisition, and development of rental office properties, with no material inter-segment transactions. The Company evaluates performance by geographic location, and the operating results by geographic grouping are regularly reviewed by the chief operating decision maker. The core portfolio consists mainly of office properties in its key markets, with the majority of revenue derived from its Raleigh properties.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.